© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 19, 1573-1581,
October 4, 2000
© 2000 Oxford University Press
Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines
Affiliations of authors: R. Mandler, A. J. Roettinger, T. A. Waldmann (Metabolism Branch, Division of Clinical Sciences), C. Wu, E. Dadachova, M. W. Brechbiel (Radioimmune and Inorganic Chemistry Section, Division of Clinical Sciences), E. A. Sausville (Developmental Therapeutics Program, Division of Cancer Treatment and Diagnostics), D. J. Newman (Natural Products Branch, Division of Cancer Treatment and Diagnostics), National Cancer Institute (NCI), Bethesda, MD; D. K. Ho, Science Applications International Corporation, NCI-Frederick Cancer Research and Development Center, Frederick, MD; C. R. King, D. Yang, M. E. Lippman, Lombardi Cancer Center, Georgetown University, Washington, DC; N. F. Landolfi, Protein Design Laboratories, Fremont, CA.
Correspondence to: Raya Mandler, Ph.D., National Institutes of Health, Bldg. 10, Rm. 4N115, 10 Center Dr., Bethesda, MD 20892 (e-mail: rayam{at}box-r.nih.gov).
Background: HER2 is a membrane receptor whose overexpression is strongly associated with poor prognosis in breast carcinomas. Inhibition of HER2 activity can reduce tumor growth, which led to the development of Herceptin, an anti-HER2 monoclonal antibody (MAb) that is already in clinical use. However, the objective response rate to Herceptin monotherapy is quite low. HER2 activity can also be inhibited by the highly cytotoxic antibiotic geldanamycin (GA). However, GA is not used clinically because of its adverse toxicity. Our purpose was to enhance the inhibitory activity of anti-HER2 MAb by coupling it to GA. Methods: We synthesized 17-(3-aminopropylamino)GA (17-APA-GA) and conjugated it to the anti-HER2 MAb e21, to form e21 : GA. The noninternalizing anti-HER2 MAb AE1 was used as a control. Internalization assays and western blot analyses were used to determine whether the anti-HER2 MAbs and their immunoconjugates were internalized into HER2-expressing cells and reduced HER2 levels. All statistical tests were two-sided. Results: The immunoconjugate e21 : GA inhibited the proliferation of HER2-overexpressing cell lines better than unconjugated e21 (concentration required for 50% inhibition = 40 versus 1650 µg/mL, respectively). At 15 µg/mL, e21 : GA reduced HER2 levels by 86% within 16 hours, whereas unconjugated e21, 17-APA-GA, or AE1 : GA reduced HER2 levels by only 20%. These effects were not caused by release of 17-APA-GA from the immunoconjugate because immunoconjugates containing [3H]GA were stable in serum at 37 °C. Furthermore, e21 : GA did not significantly inhibit proliferation of the adult T-cell leukemia cell line HuT102, which is HER2 negative yet highly sensitive to GA. Conclusions: Our findings suggest that conjugating GA to internalizing MAbs enhances the inhibitory effect of the MAbs. This approach might also be applied in cellular targeting via growth factors and may be of clinical interest.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. OKARVI and I. A. JAMMAZ Design, Synthesis, Radiolabeling and In Vitro and In Vivo Characterization of Tumor-antigen- and Antibody-derived Peptides for the Detection of Breast Cancer Anticancer Res, April 1, 2009; 29(4): 1399 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mandler, H. Kobayashi, E. R. Hinson, M. W. Brechbiel, and T. A. Waldmann Herceptin-Geldanamycin Immunoconjugates: Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity Cancer Res., February 15, 2004; 64(4): 1460 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nishiyama, A. Nori, A. Malugin, Y. Kasuya, P. Kopeckova, and J. Kopecek Free and N-(2-Hydroxypropyl)methacrylamide Copolymer-bound Geldanamycin Derivative Induce Different Stress Responses in A2780 Human Ovarian Carcinoma Cells Cancer Res., November 15, 2003; 63(22): 7876 - 7882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman The Hsp90 chaperone complex as a novel target for cancer therapy Ann. Onc., August 1, 2003; 14(8): 1169 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Park, M. W. Yeh, M. G. Wong, M. Lobo, W. C. Hyun, Q.-Y. Duh, and O. H. Clark The Heat Shock Protein 90-Binding Geldanamycin Inhibits Cancer Cell Proliferation, Down-Regulates Oncoproteins, and Inhibits Epidermal Growth Factor-Induced Invasion in Thyroid Cancer Cell Lines J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3346 - 3353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Frankel New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002. Clin. Cancer Res., June 1, 2002; 8(6): 1699 - 1701. [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, K. Shirakawa, S. Kawamoto, T. Saga, N. Sato, A. Hiraga, I. Watanabe, Y. Heike, K. Togashi, J. Konishi, et al. Rapid Accumulation and Internalization of Radiolabeled Herceptin in an Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-enhanced Dynamic MRI with the Macromolecular Contrast Agent G6-(1B4M-Gd)256 Cancer Res., February 1, 2002; 62(3): 860 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. A. Elsayed and E. A. Sausville Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins Oncologist, December 1, 2001; 6(6): 517 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Blagosklonny and A. B. Pardee Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells Cancer Res., June 1, 2001; 61(11): 4301 - 4305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mendelsohn Use of an Antibody to Target Geldanamycin J Natl Cancer Inst, October 4, 2000; 92(19): 1549 - 1551. [Full Text] [PDF]
|
|